Plasma GH as a diagnostic and prognostic biomarker in HCC without cirrhosis.

• DOI: 10.1200/jco.2019.37.4_suppl.227
• Publication Date: 2019-01-29T23:13:19Z
• Authors: Roberto Carmagnan...; Manal Hassan; Reham Abdel-Wahab; Yehia I. Abugabal; Lauren Girard; Rikita Hatia; Van Nguyen; Kanwal Pratap Sin...; Jeffrey Morris; Asif Rashid; Robert A. Wolff; Hesham M. Amin; Ahmed Omar Kaseb
• Keywords: Hepatocellular cancer

227 Background: The association between the GH/IGF-1 axis and HCC was reported in patients (pt) with underlying cirrhosis. However, there is limited information among pt without (w/o) We herein investigated role of GH as a circulating biomarker for diagnosis prognosis w/o Methods: Under IRB approval, we prospectively enrolled 1267 newly-diagnosed case control study at MD Anderson Cancer Center (2000-2015). Controls were healthy individuals (n = 1104). Plasma AFP measured 274 cirrhosis 200 controls. IGF-1 133 82 pt, respectively. classified into higher lower values (cutoff women, 3.7 µg/L; men, > 0.9 µg/L). Results: Most (74%) male, advanced BCLC staging (C-D, 74%) 61% older than 60y. Baseline (mean 3.3 µg/L) controls 0.4 µg/) (p < .001). ROC curve plotted to assess diagnostic role. AUC 82.9 .001); 78.2 When only non-cirrhotic early stage (CLIP 0-2) 20 ng/m compared controls, ratio had high prediction - 83 (95% CI 78-89%) .0001). At specificity 90%, sensitivity GH/IGF 67%. In addition, cirrhosis, levels correlated presence vascular invasion .001) thrombosis .004), tumor involvement 50% liver .003), more TNM Median overall survival (months) 13.1 (10.8-15.4) 37.4 (19.8-55.1) plasma Multivariate cox-regression analysis identified an independent risk factor mortality (HR 1.8; 95% CI, 1.3-2.4; p Conclusions: Our demonstrates prognostic identifies promising marker low AFP; this excludes confounding effect hepatocyte impaired function by Further studies are warranted causes observed differences.